Five pharma CDMO stocks with robust revenue growth in Q2FY27
New Delhi, Nov. 21 -- Global pharmaceutical companies are increasingly outsourcing research and manufacturing to diversify supply chains and lower costs.
Indian contract development and manufacturing organisations (CDMOs) have emerged as key beneficiaries, moving up the value chain into complex custom synthesis, peptides, and specialty intermediates.
While broader pharmaceutical earnings remained mixed in the September 2026 quarter, select CDMO stocks stood out with strong commercial scale-up and delivered robust revenue growth in Q2FY27. Take a look.
#1 Blue Jet Healthcare
Blue Jet Healthcare is a speciality pharmaceutical CDMO engaged in developing and manufacturing advanced intermediates, APIs and high-intensity sweeteners.
Its bu...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.